Promising clinical trials surrounding this compound, specifically the 120 milligram formulation referred to as ZPHC, indicate a considerable effect on physique decrease and associated metabolic conditions . Scientists anticipate that this innovative agonist , affecting both GLP-1 and GIP receptors , could offer a noteworthy breakthrough in the tre